Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study

Table 1

Baseline characteristics.

Characteristics	Combination therapy group (n = 55)
Patient origin no. (%)
Zhejiang	26 (47.3)
Shanghai	25 (45.5)
Tianjin	4 (7.3)
Median age, years	53 (27–82)
Sex
Male	19 (34.5%)
Female	36 (65.5%)
Histology
Cutaneous	41 (74.5%)
Acral	12 (21.8%)
Unknown	2 (3.6%)
Stage
IIIA	3 (5.5%)
IIIB	11 (20%)
IIIC	27 (49.1%)
IIID	7 (12.7%)
III unspecified	7 (12.7%)
Primary tumor ulceration
Yes	32 (58.2%)
No	19 (34.5%)
Unknown	4 (7.3%)
BRAF status
V600E	51 (92.7%)
V600K	4 (7.3%)